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Telomere biology is central to the maintenance of genomic stability and telomeric dysfunc-
tion is thought to be an early stage in carcinogenesis. Reports of telomere lengths and their
ascribed colorectal cancer (CRC) risks have been discordant, with both very short and very
long telomeres implicated. Nevertheless, telomeres appear to play a very central role in
cancer initiation. Telomere length changes also appear to impact disease burden, progres-
sion, and overall survival. This review covers contemporary views on telomere biology and
CRC risk, with a brief overview of analytical methods employed in telomere measurement.
We conclude with arguments in favor of including telomere assessment in the molecular
profiling of CRCs.
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INTRODUCTION
Telomeres are repeat TTAGGG sequences at the end of linear
chromosomes, which guard against loss of genetic material during
cellular replication. Due to an inherent end replication problem,
chromosomes are exposed to a potential loss of genetic mater-
ial, with telomeres acting as a buffer against loss of chromatin.
Repeated cell cycles eventually lead to a critically shortened telom-
ere length, signaling cellular senescence, and triggering apoptosis.
This arrest in proliferation is thought to protect against malig-
nant transformation and a failure to do so results in catastrophic
genomic instability and carcinogenesis. Telomeres are thus impor-
tant in managing genomic stability. This central role in genome
maintenance makes telomeres key players in carcinogenesis and
an attractive candidate for tumor profiling at the molecular level.
TELOMERES AND COLORECTAL CANCER
Telomere length changes have been linked to numerous cancers,
including colorectal cancer (CRC). Results from studies analyz-
ing telomere lengths in CRC have been discordant, presenting
evidence that both ends of the spectrum (shorter and longer
lengths) have a possible role in CRC occurrence (1–3). More-
over, reports of null association have been described (1, 4, 5).
Nevertheless, studies linking telomere attrition, or shortening,
to an increase in CRC risk have classically dominated litera-
ture. Telomeric dysfunction is thought to represent an early step
in many epithelial cancers (6). As telomeres reach their criti-
cal length, senescent signals are sent, and cells undergo cellular
arrest and apoptosis. By-passing this senescent signal and cel-
lular arrest results in continuous replication, with progressive
telomere shortening. Eventually telomeres become so short that
end-to-end fusions with structural and numerical chromosomal
changes, anaphase bridging, and subsequent chromosomal insta-
bility ensue (7). This so-called telomere catastrophe halts further
cellular divisions (8). However, in the presence of loss of tumor
suppressor function, such as an APC mutation or p53 inactivation,
pre-malignant cells are able to by-pass this event through telom-
ere maintenance mechanisms. Telomerase, a ribonucleoprotein
reverse transcriptase, stabilizes the telomere lengths, protecting the
altered chromosomes,and immortalizing pre-malignant cells, thus
enabling cancer progression (9, 10). This telomerase upregulation
occurs at the critical point in the adenoma-carcinoma transition,
allowing evasion of telomeric catastrophe, and supporting malig-
nant progression (see Figure 1) (3, 11). Less-commonly, telomere
length may be preserved through a recombination-dependent
mechanism (12).
The tumor micro-environment may also contribute to car-
cinogenesis. Shortened telomeres in stromal cells may partic-
ipate in epithelial changes leading to cancer via autocrine or
paracrine mechanisms. Thus as stromal cells undergo senescence,
they exhibit a secretory phenotype that may trigger neighboring
cells with shortened telomeres to by-pass the senescence signal
and termination, setting the stage for chromosomal instability
and malignant transformation (13). This theory, known as the
senescence-associated secretory pathway, could explain the finding
that shortened telomere lengths in some polyps and CRC mirrored
the shortened telomeres in the surrounding tissue, suggesting
that a shortened telomere length may predate malignant trans-
formation and is not a consequence of cancer progression (14).
Chronic inflammation processes in surrounding epithelial cells, as
in chronic ulcerative colitis, has also been linked to an increased
telomere attrition rate and malignant progression, giving credence
to the theory that telomere shortening in the micro-environment
may act as a nidus for malignant transformation (15).
Epidemiological studies evaluating the relationship between
telomere lengths and CRC risks have produced conflicting results.
Although telomere attrition is classically thought of as a risk for
CRC, reports of longer telomere lengths, and a predisposition
to CRC have emerged (2, 16–18). To complicate matters, some
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FIGURE 1 |Telomere length and its relationship to cell division, senescence, and senescence by-pass.
studies report a duality of results, with both shorter and longer
telomeres associated with increased CRC risk (1, 18). Interestingly,
the findings of longer telomeres and their association to CRC seem
prevalent in prospective studies, while retrospective studies report,
for the most part, shorter telomere lengths. Pooley et al. report an
association of shortened telomere lengths and CRC risk in ret-
rospectively collected samples, but fail to replicate their results
in the prospective arm of their study (1). Given the conflicting
results with respect to study timeline, the argument of reverse
causality has been made. Simply put, the changes in telomere
lengths, especially in the case of shorter telomeres, may repre-
sent disease progression and/or therapeutic interference. Shorter
telomere lengths could therefore be a marker of disease progres-
sion rather than one of causality. Moreover, the dual findings that
both extremely short and long telomeres may be associated with
CRC, sometimes within the same sample set, point to the possi-
bility of a “healthy range” of telomere lengths within which cancer
risk need not be increased.
ASSESSMENT OF TELOMERE LENGTH
A multitude of analytical techniques are available for telomere
length measurement, including Southern Blot, quantitative PCR
(qPCR), flow cytometry with fluorescence in situ hybridization
(flow-FISH), quantitative FISH (Q-FISH), and single or univer-
sal single telomere length analysis (STELA) (19). Southern Blot
and qPCR are the two most commonly used techniques in epi-
demiological studies assessing peripheral blood leukocyte (PBL)
telomere length. Southern Blot analysis is the gold standard for
telomere length assessment, providing results, in terminal restric-
tion fragment (TRF) units, that are deemed reproducible and that
allow inter-study comparisons. However, Southern Blot analysis
requires a large amount of high-quality DNA and may exaggerate
telomere length by including subtelomeric DNA (20). Further-
more, the type of restriction endonuclease used may impact
measurement results (20). Cancer risk association studies typi-
cally use qPCR to determine telomere lengths. qPCR uses primers
to the telomeric repeats to amplify telomeres (21). The telom-
ere to single copy gene ratio of the sample is then compared to
the ratio of a reference DNA sample, yielding a relative telomere
length (21). qPCR does not require a large amount of DNA but
inter-laboratory differences in the reference DNA limit compar-
isons between studies. The estimated variability between assays
is >6% for qPCR and >2% for Southern Blot (22). Telomerase
activity may also be measured by way of the Telomere Repeat
Amplification Protocol (TRAP), which utilizes PCR to amplify
telomerase-extended primer products (23). Alternatively, telom-
erase activity can be measured via a direct primer extension activity
assay, which has proven effective in cell assays but has as yet to be
applied to tissues. This direct extension assay avoids the limitations
of the TRAP assay, which can be less accurate due to non-linear
amplification and due to false negative results in the presence of
inhibitors of Taq DNA polymerase (24). hTERT mRNA expression
using real-time PCR has also been used to characterize telomerase
activity. hTERT mRNA expression is thought to provide a good
correlation with telomerase activity in certain cancers, including
CRC and has been suggested to have a negative prognostication
value in CRC (25, 26). Given the wide range of analytical tools
available, it is not unreasonable to assume that some of the dis-
crepancies in published results may be due to measurement error
and inter-laboratory variation. In a large study, Cunningham et al.
find that DNA extraction methods greatly influenced telomere
length readings (27). A standardized extraction and measurement
method is therefore imperative to allow comparison and validation
of published data.
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TELOMERES AND MOLECULAR SUBCLASSIFICATION OF CRC
The lack of consensus on telomere length changes and the con-
ferred risk for CRC could point toward the existence of distinct
molecular subclasses of CRC. Telomere dysfunction may repre-
sent an alternative pathway in CRC carcinogenesis, a shift from
the two classic genomic instabilities observed: chromosomal and
microsatellite instability (MSI). In a study assessing telomere
attrition in microsatellite stable (MSS) and chromosomally sta-
ble (CIN−) rectal cancers, Boardman et al. revealed evidence
of molecular heterogeneity within MSS cancers, in regards to
their CIN status and telomere maintenance mechanism (16). Of
interest was the discovery of a subset of MSS and CIN-rectal
cancers with the unique molecular profile of increased alterna-
tive lengthening pathway (ALT+) and longer telomere lengths,
in contrast to the shortened telomeres and increased telomerase
expression in the chromosomally unstable (CIN+) subgroup (16).
Although ALT expression has been described in various can-
cers, its association to CRC is not clearly defined (28, 29). ALT
offers a distinct telomere maintenance mechanism from telom-
erase, involving superimposed lengthening and shortenings in a
recombination-dependent fashion (30). The results are long, het-
erogeneous telomeres, and the pathognomonic ALT associated
promyelocytic leukemia bodies (APBs) (28). From this perspec-
tive, the distinct molecular profiles observed could point to the
existence of a different molecular subclass of CRC. In a separate
study, the authors also find an age at onset-dependent differ-
ence in PBL telomere length changes and CRC risk (31). Longer
PBL telomeres appear to be a predictor of CRC in their young-
onset CRC subgroup (≤50 years old) while extremely short PBL
telomeres are associated with CRC in older individuals. While
shorter telomere lengths in the older subgroup (≥50-year-olds)
may partly be explained by the natural aging process and resul-
tant chromosomal instability, the association of longer telomeres
and CRC risk in younger patients may suggest genetic alterations
in telomere maintenance mechanisms. While reverse causality,
or the effect of disease burden and therapy, may certainly be
an explanation for the longer telomere lengths observed, the
result may also indicate a diverging telomere-centered mechanism,
and potentially, a distinct molecular subclass of CRC with early
penetrance.
Studies looking into the relationship between MSI and telomere
lengths have been sparse. Telomeres may be considered a form of
super microsatellite given their tandem repeat nature and it may be
reasonable to assume that defects in MMR genes impact telomere
length. In an experiment studying the effect of down-regulating
MSH2 in fibroblast cell lines, Mendez-Bermudez et al. report a sta-
tistically significant increase in telomere attrition rate compared
to control cell lines (32). However, we do not fully understand how
these findings might translate into the prognosis and treatment of
patients with dMMR CRC.
The impetus for adding telomere lengths to the molecular pro-
filing of CRC lies in the possibility of tailored therapy. Differences
in molecular profiles often translate into distinct clinical progres-
sion, as in the case for CIN− and CIN+ CRC. Genetic CRC
may also benefit from a telomeric subclassification, as telomere
length changes have been suggested as risk modifiers in mutation
carriers and therefore may serve as a marker of prediction (33). The
association between telomere length and disease progression has
been described, both in early and more advanced cases (34, 35).
Riegert-Johnson et al. report shorter PBL telomere in individu-
als with advanced polyps compared to age- and gender-matched
polyp-free individuals, suggesting that PBL telomere be used as a
biomarker for advanced adenomatous polyps (34). This biomarker
for stratifying patients according to their progression risks could
serve as a pre-screening step, identifying patients needing more
frequent colonoscopic surveillance. Telomerase activity has also
been suggested as a marker for progression, with numerous reports
on the association between increased telomerase expression and
malignant transformation (3, 11). Telomerase activity appears to
correlate to disease stage, with Duke A and B stages expressing
lower telomerase activity (36). Furthermore, telomerase activity
reflected disease burden, risk of recurrence, and overall survival
(11, 26, 37). Thus, quantifying telomere length and telomerase
activity may serve as a useful prognostication tool.
There has been intense interest in anti-telomerase drugs and
their potential as a targeted chemotherapeutic drug (38, 39). Tar-
geted therapy could reduce treatment-resistance and side-effects.
The combination of a telomere-centered subclassification and tar-
geted treatment could translate into individualized medical care
and better patient outcomes. Determining telomeric molecular
profiles and their ascribed cancer risk also opens the possibility
for chemoprevention.
CONCLUDING REMARKS
Very like the chicken or egg causality dilemma, the timeline of
events involving telomeres, genomic instability, and CRC remain
unclear. While distinct molecular mechanisms are conceivable,
synergistic effects between different components and the inter-
actions of alternative pathways cannot be ignored. Differences in
analytic measures have been implicated in the varying results seen
suggesting the need for a standardized measurement technique.
The difference in results could also reflect a reverse-causation
effect. Larger prospective studies are imperative to validate pre-
viously published data. Moreover, given the duality in findings,
a healthy range of telomere lengths may need to be established.
Nevertheless, a subclassification of CRC to include telomere sta-
tus could carry significant value in predicting disease severity,
progression and overall prognosis, and in directing treatment. A
telomere subclassification represents an important step forward in
individualized medicine and is, therefore, an important avenue to
explore.
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